Acetylcholinesterase (AchE) receptor-based In-Silico drug discovery for Alzheimer’s Disease

17 November 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

In Alzheimer’s disease acetylcholine esterase is a lead enzyme for increasing the patient health. The current most effective drug donepezil in this paper the donepezil core which is not participating in receptor-ligand binding was substituted with another core and the the library was prepared. Computer-aided drug design (CADD), especially in the field of structure-based plays a significant role in the design and optimization of drug-like molecules, in CADD virtual screening remains at the top, the virtual screening is used to screen the library generated against the receptor. Molecular docking analysis was used for the analysis of the analyzing the ligand and receptor docking. The docked compounds were then further analyzed to check their drug-likeness properties and the parameters like receptor-ligand binding energy and their modes of interaction distance from the active site of the receptor were done further synthetic and biological assays can be performed for a details analysis of drug activity and study of the pharmacokinetics and pharmacodynamic properties of the drug.

Supplementary materials

Title
Description
Actions
Title
ADMET profile
Description
The ADME properties of the lead molecules assigned in the research paper, Values are derived from SwissADME (http://www.swissadme.ch/) web-based software
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.